Blood pressure drug recall issued after wrong pills found in bottles

Health Canada is warning the public that two lots of MAR-Amlodipine 5 mg tablets are being recalled after some bottles were found to contain the wrong medication.

The recall, issued by Marcan Pharmaceuticals Inc., affects MAR-Amlodipine 5 mg (DIN 02371715), lots 2472021 and 2472021A, with expiry dates of July 2027.

Health officials say some bottles may contain midodrine 2.5 mg tablets instead of amlodipine. MAR-Amlodipine is prescribed to treat high blood pressure and chest pain, while midodrine is used to treat low blood pressure. Taking midodrine instead of amlodipine could cause a dangerous rise in blood pressure, along with dizziness, fainting and potential organ damage.

Correct MAR-Amlodipine tablets are described as white to off-white, flat and eight-sided, with a score line across the middle. One side is marked “210” and “5,” while the other side is blank. The incorrect midodrine tablets are white, round and marked “M2” on one side with a score line on the other.

Health Canada says some people may not notice symptoms even if their blood pressure rises, increasing the risk of serious harm. Children and patients with certain medical conditions, including glaucoma or thyroid disorders, could face additional risks if they take the wrong tablets.

Patients are being urged to check their medication bottles immediately. Anyone who finds round tablets in a MAR-Amlodipine bottle should return it to their pharmacy for a replacement and should not take the round tablets. If a replacement is not immediately available, patients may continue taking their medication as directed but should avoid any round tablets.

People experiencing dizziness, unusually high blood pressure or slow heartbeats are advised to contact a health professional or call 911. Immediate medical attention is recommended for chest pain, sudden severe headache, difficulty speaking or trouble moving or feeling part of the body.

Pharmacists are also being asked to inspect stock before dispensing and to report any affected bottles.

Health Canada says it is monitoring the recall and the company’s investigation and will provide updates if additional risks are identified.